

Effective and Timely Management of Patients with T2DM: A Case-based Approach

Bibliography

Abdul-Ghani M. *Diabetes Care*. 2016;39:717-725.

ADA. *Diabetes Care*. 2014;37(Suppl 1):S14-S80.

Afrezza (insulin human). Prescribing information. Available at: <http://products.sanofi.us/afrezza/afrezza.html>.

Ahrén B. *Curr Diab Rep*. 2003;2:365-372.

<http://www.ahrq.gov/workingforquality/nqs/overview.htm>

Ali MK et al. *N Engl J Med*. 2013;368:1613-1624.

Allen J, Freitas S. Comparison chart of glucose-lowering agents for management of type 2 diabetes mellitus. October 2015.

American Diabetes Association Standards of Medical Care in Diabetes. Cardiovascular disease and risk management. *Diabetes Care*. 2016;39(Suppl 1):S60-S71.

American Diabetes Association Standards of Medical Care in Diabetes. Glycemic targets. *Diabetes Care*. 2016;39 (Suppl 1):S39-S46

Baig AA et al. *Med Care Res Rev*. 2010;67(5 Suppl):163S-197S.

Bakris GL et al. *Kidney Int*. 2009;75:1272-1277.

Blonde L et al. *Lancet*. 2015;385:2057-2066.

Bolli GB et al. *Diabetes Obes Metab*. 2015;17:386-394.

Brooks M. FDA sides with EMA on incretin diabetes drugs. 8-1-2013. Available at: www.medscape.com/viewarticle/808830.

Brown JB et al. *Diabetes Care*. 2004;27:1535-1540.

CDC Behavioral Risk Factor Surveillance Systems; CDC Diabetes Public Health Resource Center.

CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: US Department of Health and Human Services, 2014.

Centers for Medicare & Medicaid Services. Available at: <https://www.cms.gov>.

Chang CH et al. *Medicine (Baltimore)*. 2016;95:e2603.

Davies M et al. *Diabetes Obes Metab*. 2009;11:1153-1162.

Davies M et al. *Diabetes Care*. 2013;36:1368-1376.

Del Prato S, Marchetti P. *Horm Metab Res*. 2004;36:775-781.

DeFronzo RA. *Diabetes*. 2009;58:773-795.

Diamant M et al. *Lancet*. 2014;2:464-473.

Diamant M et al. *Lancet*. 2010;375:2234-2243.

Diamant et al. *Diabetes Care*. 2014;37:2763-73.

Drucker DJ. *Diabetes Care*. 2003;26:2929-2940.

Drucker. *Curr Pharm Des*. 2001;7:1399-1412.

Drucker. *Mol Endocrinol*. 2003;17:161-171..

Eli Lilly and Co. Trulicity (dulaglutide) prescribing information. Available at: <http://pi.lilly.com/us/trulicity-uspi.pdf>.

Evans M, McEwan P. *J Comp Eff Res*. 2015:1-8. [Epub ahead of print].

FDA. FDA Drug Safety Communication. 3-14-2013. Available at: www.fda.gov/drugs/drugsafety/ucm343187.htm.

FDA Drug Safety Communication. 4-8-16. Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf>.

FDA. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>

FDA news release. 12-16-15. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm>.

Garber AJ et al. *Endocr Pract*. 2016;22:84-113.

Gough SC et al. *Lancet Diabetes Endocrinol*. 2014;2:885-893.

Funnell MM. *Fam Pract*. 2010;27: i17–i22.

Heine R et al. *Ann Intern Med*. 2005;143:559-569.

Hirsch I. *N Engl J Med*. 2005;352:174-183.

Holman et al. *N Engl J Med*. 2008;359:1577-1589.

Holst JJ et al. *Diabetes*. 2004;53(suppl 3):s197-s204.

Holst JJ. *Diabetes Metab Res Rev*. 2002;18:430-441.

Inzucchi SE et al. *Diabetes Care*. 2015;38:140-149.

Inzucchi SE et al. *JAMA*. 2014;312:2668-2675.

Inzucchi SE et al. *Diabetes Care*. 2012;35:1364-1379.

Kahn CR, Saltiel AR. *Joslin's Diabetes Mellitus*. 14th ed. Lippincott Williams & Wilkins; 2005:145-168.

Kieffer TJ, Habener JF. *Endocr Rev*. 1999;20:876-913.

Kim Y et al. *Diabetes Metab Syndr Obes*. 2012;5:313-327..

Khunti K, et al. *Br J Diabetes Vasc Dis*. 2015;15:65-69.

Lee EO et al. *N Engl J Med*. 2013;368:6-8.

Leiter LA et al. ADA 2014 Annual Meeting. Abstract 994-P.

Marsenic O. *Am J Kidney Dis*. 2009;53:875-883.

Marso SP et al. *N Engl J Med*. 2016;Jun 13. [Epub ahead of print]. Presentation at ADA Scientific Sessions, June 13, 2016, session 3-CT-SY24.

Mathieu et al. *Diabetes Obes Metab*. 2014;16:636-44.

Mayo Foundation for Medical Education and Research. Diabetes medication choice, 2014. Available at: <http://shareddecisions.mayoclinic.org>.

Medline Plus. <https://www.nlm.nih.gov/medlineplus/ency/imagepages/19815.htm>. Accessed: 12/5/2015.

Meier JJ et al. *Diabetes Metab Res Rev*. 2005;21:91-117.

Meier JJ. *Nat Rev Endocrinol*. 2012;8:728-742.

Meneghini L et al. *Diabetes Care*. 2013;36:858-864.

Müller WA et al. *N Engl J Med*. 1970;283:109-115.

Nathan DM et al. *Diabetes Care*. 2009;32:193-203.

Nauck M et al. *Diabetologia*. 1996;29:46-52.

Paul S et al. *Cardiovasc Diabetol*. 2015;14:100. Published online 2015 Aug 7. doi: 10.1186/s12933-015-0260-x.

Phillips LS et al. *Ann Intern Med*. 2001;135:825-834.

Physician's Desk Reference. Montvale, NJ. Thomson PDR; 2013.

Physicians' Desk Reference. Montvale, NJ: PDR Network; 2014

Plank J et al. *Diabetes Care*. 2005;28:1107-1112.

Porte D Jr, Kahn SE. *Clin Invest Med*. 1995;18:247-254.

Qaseem A et al. *Ann Intern Med*. 2012;156:218-231.

Ratner R et al. *Diabetes Obes Metab*. 2013;15:175-184.

Rave K et al. *Diabetes Care*. 2005;28:1077-1082.

Riddle MC et al. *Diabetes Care*. 2014;37:2755-2762;

Rosenstock J et al. eds. *Textbook of Type 2 Diabetes*. 2003:131-154.

Rosenstock et al. *Diabetes Care*. 2014;37:2317-25.

Rosenstock J et al. *Diabetologia*. 2014;57(suppl 1) [abstract 241].

Russell-Jones D et al. *Diabetologia*. 2009;52:2046-2055.

Stark Casagrande S et al. *Diabetes Care*. 2013;36:2271-2279.

Stratton IM et al. *BMJ*. 2000;321:405-412.

UKPDS Study Group. *Lancet*. 1998;352:837-853.

US FDA. Drugs@FDA. Available at: <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA>.

VA. Shared Decision Making with the Patient with Diabetes. 2012.

Wang T et al. *Diabetes Obes Metab.* 2015;17:32-41.

Wanner C et al. *N Engl J Med.* 2016;Jun 14. [Epub ahead of print].

Woerle HJ et al. *Am J Physiol Endocrinol Metab.* 2003;284:E716-E725.

Yki-Järvinen H et al. *Diabetes Care.* 2014;7:3235-3243.